Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Numbers needed to treat to prevent tuberculosis

Martina Sester, Reinout van Crevel, Frank van Leth, Christoph Lange
European Respiratory Journal 2015 46: 1836-1838; DOI: 10.1183/13993003.01047-2015
Martina Sester
1Dept of Transplant and Infection Immunology, Saarland University, Homburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: martina.sester@uks.eu
Reinout van Crevel
2Dept of Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank van Leth
3Dept of Global Health, Academic Medical Center, University of Amsterdam and Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christoph Lange
4Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany
5German Center for Infection Research, Tuberculosis Unit, Borstel, Germany
6International Health/Infectious Diseases, University of Lübeck, Lübeck, Germany
7Dept of Medicine, Karolinska Institute, Stockholm, Sweden
8Dept of Medicine, University of Namibia School of Medicine, Windhoek, Namibia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Comparing the NNT to prevent one case can help define groups at highest TB risk and prioritise prevention strategies http://ow.ly/TITzR

To the Editor:

A new action framework advocacy document for tuberculosis elimination in low-incidence countries has recently been published in this journal [1]. We completely agree with the importance of addressing the goal of elimination of tuberculosis, which may be achievable in regions such as Western Europe and North America, but we are concerned that this goal may be overly ambitious at this point in time. As protective immunity can, unfortunately, not be achieved by a vaccine or other immune-based intervention, tuberculosis control still relies on early identification and treatment of active tuberculosis, and preventive chemotherapy of individuals with latent Mycobacterium tuberculosis infection (LTBI). However, both the tuberculin skin test (TST) and interferon-γ release assays (IGRAs) (the ELISA-based QuantiFERON-TB Gold In-Tube assay (QIAGEN, Venlo, the Netherlands) or the ELISPOT-based T-SPOT.TB assay (Oxford Immunotec, Oxford, UK)) that are recommended to diagnose LTBI have a low positive predictive value for the future development of tuberculosis, and are therefore insufficient as biomarkers to identify individuals developing active disease. With tuberculosis being a rare event, the vast majority of individuals with positive test results will never develop disease [2]. Moreover, in immunocompromised individuals, especially in patients with HIV infection, the negative predictive value of an immunodiagnostic test is insufficient to rule out the future development of tuberculosis, as was recently demonstrated in a large study in Europe [3]. Thus, systematic testing and treatment of LTBI of risk groups [1] is considered difficult to implement.

In order to optimise allocation of the available resources for tuberculosis elimination, the first step would be an improvement in the knowledge of risk groups for tuberculosis in low-incidence countries. More recently, it has become evident that the risk of the development of tuberculosis among patient groups classically considered at risk is highly variable, and is not necessarily associated with the results of immunodiagnostic testing by the TST or IGRAs [2–5]. More detailed knowledge of groups at actual risk of tuberculosis and on immunodiagnostic test performance in these risk groups may provide better guidance for physicians on priorities for targeting tuberculosis testing and LTBI treatment in low-incidence countries.

The decision to administer prophylactic treatment to a certain risk group should depend on the estimated number needed to treat to prevent one case of tuberculosis. Although not selected by a systematic approach, we made use of the fact that several studies with large sample sizes from low-incidence countries of tuberculosis were recently published from three major groups classically considered at risk for progression. In these studies, tuberculosis contacts [2, 4, 5], immunocompromised hosts [3] and healthcare workers [6–8] were evaluated for LTBI and subsequent progression. We have calculated the number needed to treat to prevent one case of tuberculosis (table 1), and found that the number needed to treat was very similar across three studies evaluating 1579, 5020 and 4774 tuberculosis contacts, respectively, with a positive TST or IGRA, ranging from 30 to 37 [2, 4, 5] (table 1). In immunocompromised individuals with a positive test (n=1537) [3], the number needed to treat to prevent a case was higher and ranged from approximately 50 to 80 (table 1). Notably, as incident cases of tuberculosis were mainly HIV positive, the number of HIV-infected persons with a positive test needed to treat was lower (range 14.0–25.5) and tuberculosis cases were only found in patients with ongoing viral replication [3]. It should be emphasised that incident tuberculosis cases also occurred in individuals with negative test results [2, 3, 5], especially among patients with HIV infection. In patients with chronic renal failure (n=270) or rheumatoid arthritis (n=199), stem cell (n=103) or solid organ transplant recipients (n=197) [3], and healthcare workers (n>15 000) [6–8], the number of individuals with LTBI needed to treat to prevent one case could not be calculated because no tuberculosis cases occurred during 2 years of follow up in these cohorts.

View this table:
  • View inline
  • View popup
TABLE 1

Numbers of individuals with positive immunodiagnostic results needed to treat (NNT) to prevent a case of tuberculosis

In the absence of better biomarkers [9], comparing the number needed to treat to prevent one case is helpful to define groups with highest risk of developing tuberculosis and to prioritise existing prevention strategies. These strategies should particularly focus on HIV-infected individuals, preferentially with ongoing viral replication, and on close contacts of infectious cases of tuberculosis, although higher numbers are needed to screen and treat among contacts. In contrast, given the low number or even absence of incident cases in other groups classically considered at risk, screening approaches more closely targeted to individuals with additional risk factors would seem more effective to identify candidates who will most likely benefit from preventive chemotherapy [10]. Finally, some groups formerly considered at risk of tuberculosis (e.g. healthcare workers) are no longer risk groups in low-incidence countries [6–8], unless having had substantial contact to a patient with tuberculosis. It should be stated that given the inadequate test characteristics of the current diagnostics, not all tuberculosis will be prevented by these strategies, since active disease will continue to occur in those tested negative.

Footnotes

  • Conflict of Interest: Disclosures can be found alongside the online version of this article at erj.ersjournals.com

  • Received June 8, 2015.
  • Accepted July 2, 2015.
  • Copyright ©ERS 2015

References

  1. ↵
    1. Lönnroth K,
    2. Migliori GB,
    3. Abubakar I, et al.
    Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J 2015; 45: 928–952.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Zellweger JP,
    2. Sotgiu G,
    3. Block M, et al.
    Risk assessment of tuberculosis in contacts by IFN-gamma release assays. A tuberculosis network european trials group study. Am J Respir Crit Care Med 2015; 191: 1176–1184.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Sester M,
    2. van Leth F,
    3. Bruchfeld J, et al.
    Risk assessment of tuberculosis in immunocompromised patients. A TBNET study. Am J Respir Crit Care Med 2014; 190: 1168–1176.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Geis S,
    2. Bettge-Weller G,
    3. Goetsch U, et al.
    How can we achieve better prevention of progression to tuberculosis among contacts? Eur Respir J 2013; 42: 1743–1746.
    OpenUrlFREE Full Text
  5. ↵
    1. Sloot R,
    2. Schim van der Loeff MF,
    3. Kouw PM, et al.
    Risk of tuberculosis after recent exposure. A 10-year follow-up study of contacts in Amsterdam. Am J Respir Crit Care Med 2014; 190: 1044–1052.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Schablon A,
    2. Nienhaus A,
    3. Ringshausen FC, et al.
    Occupational screening for tuberculosis and the use of a borderline zone for interpretation of the IGRA in German healthcare workers. PLoS One 2014; 9: e115322.
    OpenUrlCrossRefPubMed
    1. Dorman SE,
    2. Belknap R,
    3. Graviss EA, et al.
    Interferon-gamma release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States. Am J Respir Crit Care Med 2014; 189: 77–87.
    OpenUrlPubMedWeb of Science
  7. ↵
    1. Slater ML,
    2. Welland G,
    3. Pai M, et al.
    Challenges with QuantiFERON-TB Gold assay for large-scale, routine screening of U.S. healthcare workers. Am J Respir Crit Care Med 2013; 188: 1005–1010.
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    1. Chegou NN,
    2. Heyckendorf J,
    3. Walzl G, et al.
    Beyond the IFN-γ horizon: biomarkers for immunodiagnosis of infection with Mycobacterium tuberculosis. Eur Respir J 2014; 43: 1472–1486.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. van Leth F,
    2. van Crevel R,
    3. Brouwer M
    . Latent tuberculosis infection as a target for tuberculosis control. Future Microbiol 2015; 10: 905–908.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 46 Issue 6 Table of Contents
European Respiratory Journal: 46 (6)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Numbers needed to treat to prevent tuberculosis
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Numbers needed to treat to prevent tuberculosis
Martina Sester, Reinout van Crevel, Frank van Leth, Christoph Lange
European Respiratory Journal Dec 2015, 46 (6) 1836-1838; DOI: 10.1183/13993003.01047-2015

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Numbers needed to treat to prevent tuberculosis
Martina Sester, Reinout van Crevel, Frank van Leth, Christoph Lange
European Respiratory Journal Dec 2015, 46 (6) 1836-1838; DOI: 10.1183/13993003.01047-2015
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Airway immune responses to COVID-19 vaccination in COPD patients
  • Wider access to rifapentine-based regimens is needed for TB care globally
  • Association between immunosuppressants and outcomes of COVID-19
Show more Agora

Correspondence

  • Clinical outcomes of bronchiectasis in India
  • Reply: Clinical outcomes of bronchiectasis in India
  • Risk factors for disease progression in fibrotic hypersensitivity pneumonitis
Show more Correspondence

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society